The Internet of Things (IoT) is reshaping the management of gestational diabetes mellitus (GDM), which affects 6–9% of pregnancies worldwide. Rising obesity rates and advanced maternal age are contributing to this trend. Without proper management, GDM can lead to preeclampsia, macrosomia, neonatal hypoglycemia, and a greater risk of type 2 diabetes for mothers later in life. Traditional care depends on frequent finger‑stick blood glucose tests, dietary adjustments, and clinic visits—a demanding regimen that often misses dangerous glucose variations. IoT addresses these gaps by connecting wearable sensors, smart devices, and cloud‑based analytics to enable continuous, real‑time monitoring of glucose, vital signs, and behavior patterns. This article examines how IoT technologies are being applied to monitor and manage diabetes in pregnant women, reviews the clinical evidence supporting these tools, discusses persistent challenges, and outlines future innovations.

Understanding IoT in Healthcare

The Internet of Things refers to a network of physical devices equipped with sensors, software, and network connectivity that collect and exchange data with minimal human involvement. In healthcare, IoT shifts care from episodic, clinic‑centric models to continuous, patient‑centered approaches. Core components include:

  • Wearable sensors – devices worn on the body that track physiological parameters such as glucose, heart rate, and blood pressure.
  • Connected medical devices – smart insulin pens, continuous glucose monitors (CGMs), and automated insulin delivery systems.
  • Data aggregation platforms – cloud‑based software that processes device data using algorithms to produce insights and alerts.
  • Communication infrastructure – Bluetooth, Wi‑Fi, or cellular networks enabling data transmission from patient to provider.

These components form a continuous feedback loop: patient data is captured in real time, transmitted securely to care teams, analyzed for trends or anomalies, and used to adjust treatment—often without requiring an office visit. For pregnant women with diabetes, this loop is especially valuable because metabolic changes occur rapidly and unpredictably during gestation. For example, a CGM reading at 3 a.m. can reveal nocturnal hypoglycemia that would otherwise go undetected, prompting a pre‑emptive adjustment of basal insulin.

Gestational Diabetes: A Clinical Overview

Gestational diabetes arises when pregnancy‑induced hormonal changes impair insulin sensitivity, leading to hyperglycemia. It is typically diagnosed between 24 and 28 weeks of gestation using an oral glucose tolerance test. Management options include lifestyle modifications, oral agents like metformin, or insulin therapy. Untreated or poorly controlled GDM is associated with:

  • Maternal complications: preeclampsia, increased risk of cesarean delivery, and future type 2 diabetes.
  • Fetal and neonatal complications: macrosomia (birth weight > 4,000 g), shoulder dystocia, neonatal hypoglycemia, and long‑term metabolic programming effects.

Close glycemic monitoring is essential. The standard of care involves self‑monitoring of blood glucose (SMBG) four to six times daily using finger‑stick meters. However, patient adherence tends to decline over the course of pregnancy, and a few daily measurements can miss nocturnal hyperglycemia or post‑meal spikes. IoT‑enabled CGM addresses these limitations by providing up to 288 readings per day, creating a detailed picture of glycemic variability that supports more precise therapy decisions.

Key IoT Applications in Gestational Diabetes Management

Continuous Glucose Monitoring (CGM) Systems

Modern CGM devices—such as the Dexcom G6, Abbott FreeStyle Libre 2, and Medtronic Guardian—use subcutaneous sensors that measure interstitial glucose every 5 to 15 minutes. Many integrate with smartphone apps that display real‑time trends, sound alerts for hypo‑ or hyperglycemia, and share data with providers. For pregnant women, CGM reduces the need for painful finger‑sticks while providing a fuller picture of glycemic variability. A 2023 systematic review in Diabetes Care found that CGM use during pregnancy improved time‑in‑range by 15–20% and lowered HbA1c by 0.3–0.5% compared to SMBG alone. Another 2024 meta‑analysis in The Lancet Diabetes & Endocrinology reported that CGM reduced the risk of large‑for‑gestational‑age infants by 18% and neonatal hypoglycemia by 25% in pregnancies complicated by diabetes.

Learn more about CGM from the American Diabetes Association.

Smart Insulin Pens and Automated Delivery

Smart insulin pens (e.g., InPen, NovoPen Echo Plus) record dose timing and amount, calculate active insulin on board, and log data via Bluetooth. When paired with a CGM, these pens can generate dose recommendations or integrate with automated insulin delivery systems—often called “closed‑loop” or “artificial pancreas” systems. While most closed‑loop studies have focused on type 1 diabetes, early trials in GDM are emerging. A 2024 pilot study at the University of Colorado showed that a hybrid closed‑loop system maintained glucose targets more effectively than standard therapy in pregnant women with type 1 diabetes; similar protocols are now being tested for GDM. A 2025 feasibility study from Stanford reported that a smartphone‑based closed‑loop system achieved 72% time‑in‑range in pregnant women with type 2 diabetes, compared to 58% with usual care.

Wearable Multi‑Parameter Sensors

Beyond glucose, IoT wearables can track blood pressure (critical given the preeclampsia risk), heart rate, activity levels, sleep quality, and even uterine contractions. Devices like the Empatica E4 or medically certified smartwatches (e.g., Apple Watch with FDA‑cleared apps) transmit data to a central dashboard. Machine learning algorithms can correlate sleep disturbances with next‑day glucose patterns, or alert a provider when systolic blood pressure exceeds a threshold—enabling early intervention for preeclampsia. A 2023 study from the University of Michigan used a wrist‑worn sensor to predict preeclampsia onset three weeks before clinical diagnosis, with 89% accuracy, by analyzing heart rate variability and accelerometry signals.

Data Integration and Telehealth Platforms

IoT’s full potential is realized when device data is integrated into electronic health records (EHRs) and telemedicine platforms. Companies such as Glooko, Livongo, and Vida Health aggregate glucose, insulin, and activity data into dashboards that clinicians review during virtual visits. This integration reduces documentation burden and enables data‑driven conversations. For example, a provider can spot a pattern of post‑dinner hyperglycemia and adjust mealtime insulin via a video call, avoiding an in‑person appointment. A 2024 report from Kaiser Permanente showed that a combined CGM‑telehealth program for GDM reduced the need for endocrinologist referrals by 34% and decreased average time to therapy adjustment from 5 days to 1.5 days.

Clinical Evidence and Outcomes

The evidence base for IoT‑enabled diabetes management in pregnancy is expanding rapidly. Key findings from recent studies include:

  • Improvement in glycemic control: A randomized controlled trial published in Obstetrics & Gynecology (2022) reported that women using a CGM‑smartphone system achieved a mean fasting glucose of 88 mg/dL versus 96 mg/dL in the SMBG group (p < 0.01). The CGM group also showed lower 1‑hour postprandial glucose levels and reduced glycemic variability.
  • Reduced neonatal complications: Data from the CONCEPTT trial showed that CGM use in pregnant women with type 1 diabetes reduced neonatal intensive care admissions by 30% and large‑for‑gestational‑age infants by 19%. A 2023 follow‑up of CONCEPTT participants found that maternal CGM use was associated with improved childhood metabolic outcomes at age 5.
  • Lower maternal anxiety: Qualitative studies indicate that real‑time alerts and the ability to share data with family members reduce the emotional burden of diabetes management. A 2021 study in JMIR mHealth and uHealth found that 82% of pregnant users felt “more in control” with a CGM app, and 74% reported less worry about hypoglycemia during sleep.
  • Cost‑effectiveness signals: A 2024 health economic analysis in Value in Health estimated that CGM‑guided care for GDM saves $1,600–$2,400 per pregnancy compared to SMBG, primarily due to fewer cesarean deliveries and shorter neonatal intensive care stays.

Read the CONCEPTT trial results on PubMed.

Benefits for Pregnant Women and Healthcare Systems

The benefits of IoT in gestational diabetes management span clinical, operational, and psychological domains:

  • Real‑time alerts and early warnings: Patients and providers receive immediate notifications when glucose falls outside the safe range, enabling rapid responses and preventing severe hypoglycemia or hyperglycemia. Some platforms now include predictive alerts that warn of impending hypoglycemia up to 30 minutes in advance.
  • Patient empowerment and engagement: Seeing one’s own data visualized as trends and patterns encourages self‑management. Many apps include educational content and motivational feedback, such as daily glucose “reports” celebrating time‑in‑range achievements.
  • Reduced clinic visit burden: A 2023 analysis from Kaiser Permanente found that tele‑monitoring reduced in‑person diabetes visits by 40% among pregnant women, saving travel time and lowering exposure to infectious diseases. During the COVID‑19 pandemic, this was particularly valuable; a survey of 500 patients reported that 89% preferred the hybrid model.
  • Operational efficiency for clinics: Automated data uploads decrease the time nurses spend manually entering glucometer readings, freeing staff for direct patient care. One large obstetrics practice in Texas reported a 50% reduction in documentation time after implementing a CGM‑telehealth program.

Challenges and Limitations

Despite its promise, widespread adoption of IoT for diabetes in pregnancy faces several obstacles:

  • Data privacy and security: Continuous transmission of sensitive health data raises concerns about breaches and misuse. Compliance with HIPAA (US) and GDPR (Europe) is mandatory, but not all device manufacturers adhere equally. A 2024 audit of 10 popular CGM apps found that three shared data with third‑party analytics firms without explicit user consent. Transparent patient consent processes and robust encryption are essential.
  • Device cost and insurance coverage: CGM sensors and smart pens remain expensive out‑of‑pocket. While many insurers cover CGM for type 1 diabetes, coverage for GDM varies widely. Lower‑income populations, who already face higher GDM risk due to social determinants, may be disproportionately excluded. Advocacy groups like Beyond Type 1 and the American Diabetes Association are lobbying for expanded coverage under the Affordable Care Act.
  • Digital health literacy and access: IoT tools require smartphones, reliable internet, and the ability to interpret data. Older, non‑English‑speaking, or technologically inexperienced patients may struggle. Tailored user interfaces with multilingual support and community health worker assistance are needed to prevent widening health disparities.
  • Device accuracy in pregnancy: Physiological changes during pregnancy—increased plasma volume, altered tissue perfusion—can affect sensor calibration. Some CGM devices show slightly delayed readings or bias in the third trimester. Manufacturers are developing pregnancy‑specific calibration algorithms; a 2025 study from the University of Cambridge reported that a dedicated pregnancy algorithm improved CGM accuracy by 12% in the third trimester.
  • User adherence and alarm fatigue: Too many false or non‑actionable alerts can lead to desensitization or device abandonment. Smart threshold settings that adapt to individual glucose patterns, combined with machine learning filters that prioritize clinically significant alerts, are critical. A 2024 survey of pregnant CGM users found that 40% had turned off alarms within two weeks of starting therapy due to annoyance.

CDC Gestational Diabetes page on risk factors and prevention.

Future Directions and Innovations

The next decade will bring several advances that could make IoT‑based GDM management even more effective.

AI‑Driven Predictive Analytics

Machine learning models trained on large datasets of pregnancy glucose profiles can predict next‑hour glucose levels and recommend pre‑emptive adjustments. For example, a model might detect that a woman’s glucose tends to spike after 9 a.m. on weekdays but not weekends, correlating with work‑day breakfast habits. These personalized insights will move care from reactive to proactive. A 2025 prototype from Google Health achieved 94% accuracy in predicting nocturnal hypoglycemia in pregnant women with type 1 diabetes, using only CGM data from the preceding 6 hours.

Closed‑Loop Systems for GDM

Fully automated insulin delivery systems are already approved for type 1 diabetes. Adapting these algorithms for the shorter, more dynamic course of GDM—where insulin sensitivity changes weekly—is an active area of research. Early feasibility studies suggest that closed‑loop systems can maintain glucose targets without increasing hypoglycemia risk. A 2025 multicenter trial in the UK (the AiD‑GDM study) is currently enrolling participants to test a smartphone‑based closed‑loop system specifically designed for GDM, with results expected in late 2026.

Non‑Invasive Sensors

Efforts to replace needle‑based sensors with optical, sweat‑based, or ultrasound technologies could improve comfort and adherence. MIT’s recent prototype of a wrist‑worn Raman‑spectroscopy sensor shows promise for continuous glucose measurement without skin penetration. Another approach uses microwave‑based sensors that detect glucose changes in blood vessels beneath the skin. While still in early development, these technologies could eliminate the need for sensor insertion, reducing skin irritation and cost.

Integration with Social Determinants of Health

Future platforms may incorporate data on food access, stress levels, and community resources. For instance, an IoT‑enabled app could alert a dietician when a patient’s glucose patterns suggest she may have missed a meal due to food insecurity, enabling targeted support. A pilot program in New York City is testing a platform that combines CGM data with SNAP (Supplemental Nutrition Assistance Program) participation records to identify and assist patients with nutritional gaps.

Policy and Reimbursement Changes

Advocacy groups are pushing for expanded insurance coverage of IoT devices for all types of diabetes in pregnancy. The U.S. Preventive Services Task Force now recommends considering CGM for high‑risk pregnancies. As evidence accumulates, reimbursement policies are expected to evolve. In 2025, Medicare expanded coverage for CGM to include pregnancy as a qualifying condition, and several states have introduced bills requiring private insurers to cover CGM for GDM. If these efforts succeed, access to IoT‑enabled care could become more equitable.

Conclusion

The Internet of Things is transforming how diabetes is managed in pregnant women. By enabling continuous, remote, and data‑driven care, IoT devices help achieve tighter glycemic control, reduce complications, and empower women to take an active role in their health. Real‑world evidence demonstrates improved maternal and neonatal outcomes, reduced healthcare utilization, and high patient satisfaction. However, challenges related to cost, equity, privacy, and device accuracy must be addressed to ensure that all populations benefit. Ongoing advances in artificial intelligence, closed‑loop automation, non‑invasive sensors, and policy reform hold the potential to make IoT a cornerstone of prenatal diabetes care—delivering healthier beginnings for mothers and babies alike.